Purdue Pharma

The discovery that the 4-heteroarylpiperazine-l-carboxyanilide template can generate potent TRPVl antagonists was independently reported by three groups [76-79]. Most of the published work on this class of compounds was carried out by Purdue Pharma, and is focused on the optimization of (13a), a lead compound that had emerged from random screening of a chemical... 

The authors acknowledge helpful ideas and suggestions from C. Davidson, C. Choi, and Lane Gehrlein from Purdue Pharma. This manuscript has been presented in parts as short courses on Advanced HPLC in Pharmaceutical Analysis at Eastern Analytical Symposium 2001-2002, HPLC 2002, and Pittcon 2003. Numerous comments and suggestions from the attendees were incorporated into this manuscript. 

Analytical Sciences, Worldwide Research Development, Purdue Pharma, Ardsley, NY... 

The author acknowledges helpful ideas and suggestions from R. Ornaf, D. Barker, J. Bonilla, and C. Choi of Purdue Pharma. This chapter has been presented in parts in a symposium Regulatory compliance issues in the pharmaceutical industry at the Pittsburgh Conference in Orlando, Florida, March 13, 2003. 

The author would like to thank A1 Barckhoff, PerkinElmer LAS, for helping clarify some of the nuances in the ever-evolving system validation process and for providing valued expertise on this topic. Michael Dong of Purdue Pharma, should also be thanked for helping maintain a clear focus on the subject matter. Finally, the author would like to thank PerkinElmer LAS for making available the opportunity to write this chapter. 

The authors acknowledge valuable suggestions from Dr. M. W. Dong from Purdue Pharma L.P. 

The author is grateful to Raphael Ornaf and Michael Dong of Purdue Pharma, and Connie Ye of Novartis Pharmaceuticals Corp. for their critical review and insightfnl comments. The author would like to acknowledge David Wn of Pnrdne Pharma for the data used in the discnssion of drng discoloration. The anthor also thanks Helen Yun of Pnrdne Pharma for her help in literatnre research, and Vladimir Binshtock of Waters Corp. for providing mnch needed technical information. 

I would also like to thank Todd Miller, John Van Antwerp, and Jeff Jalinski of Waters Corporation, and Michael Dong of Purdue Pharma for their helpful ideas and review of the material included in this chapter. 

Clark K. Choi (123) Purdue Pharma, 444 Saw Mill River Rd, Ardsley, NY 10502 USA... 

Y. Vander Heyden (447) Vrije Universiteit Brussel, Faculty of Medicine and Pharmacy Dept. Pharmaceutical and Biomedical Analysis, Laarbeeklaan 103 B-1090, Brussels, Belgium Qingxi Wang (379) Pharmaceutical Research Development, Merck Research Laboratories, West Point, PA 19486 USA Mieng-Hua Wann (569) Purdue Pharma, 444 Saw Mill River Rd, Ardsley, NY 10502 USA... 

Tablets, controlled-release 10, 20, and 40 mg and 80 mg- c-ll) Various, OxyContIn (Purdue Pharma LP)...

Capsules, immediate-release 5 mg (c-ll) Oxycodone Hydrochloride (Ethex), OxylR (Purdue Pharma)... 

Tanabe Seiyaku) 1983 CCD-3693 (Purdue Pharma) Myorelaxant Sleep inductor Phase I... 

Povidone-B Betadyne Polyvinylpyrrolidone/iodine Purdue, Pharma, USA Disinfectant... 

Recently, many health advocates have become concerned with a prescription drug called OxyContin. Manufactured by Purdue Pharma, OxyContin is the brand name for the drug oxycodone hydrochloride. Concern about this drug is a result of its increasing non-medical abuse. In 2003, for example, the National Survey on Drug Use and Health found that about 2.8 million people older than 12 years of age had used OxyContin at least once non-medically. The problem, perhaps, is that OxyContin is extremely good at doing its job—pain relief. OxyContin is a powerful prescription medication used by millions of people annually to treat severe pain. 

PD-196,860 is another NR2e-specific antagonist which is under development by Purdue Pharma but still has the basic ifenprodil-like structure. It was only recently that new basic structures (e.g. iminopyrimidine) of NR2B-specific antagonists were published (Claremon et al., 2002). 

Purdue Pharma L.P. Painfully Obvious The Effects of Abusing Prescription Drugs. (March 29, 2002). . 

---